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Abstract
The breast and ovarian cancer specific tumor suppressor
BRCA1, bound to BARD1, has multiple functions aimed at
maintaining genomic stability in the cell. We have shown
earlier that the BRCA1/BARD1 E3 ubiquitin ligase activity
regulates centrosome-dependent microtubule nucleation. In
this study, we tested which domains of BRCA1 and BARD1
were required to control the centrosome function. In the
present study, (a) we confirmed that the ubiquitination
activity of BRCA1 regulates centrosome number and function
in Hs578T breast cancer cells; (b) we observed that both the
amino and carboxyl termini of BRCA1 are required for
regulation of centrosome function in vitro ; (c) an internal
domain (770-1,290) is dispensable for centrosome regulation;
(d) BARD1 is required for regulation of centrosome function
and protein sequences within the terminal 485 amino acids
are necessary for activity; and (e) BARD1 is localized at the
centrosome throughout the cell cycle. We conclude that the
BRCA1-dependent E3 ubiquitin ligase functions to restrain
centrosomes in mammary cells, and loss of BRCA1 in the
precancerous breast cell leads to centrosomal hypertrophy,
a phenotype commonly observed in incipient breast cancer.
(Cancer Res 2006; 66(8): 4100-7)
Introduction
The breast and ovarian cancer specific tumor suppressor BRCA1
is a multifunctional phosphoprotein that maintains genomic stabi-
lity in the cell by participating in cell cycle regulation, DNA repair,
and transcription (1). Composed of 1,863 amino acid residues, the
amino-terminal 109 residues of BRCA1 contain a RING domain,
a motif that mediates ubiquitin ligation, initially shown using
the isolated RING domain (2). Subsequently, it was found that
BRCA1 ubiquitin ligase activity is markedly enhanced when it is
in complex with another RING finger protein, BARD1 (3, 4).
The only other domain of BRCA1 with a recognizable motif is
the carboxyl terminus, which encodes two tandem BRCT repeats
(BRCA1 carboxyl-terminal domain) found in proteins involved in
DNA binding and repair (5). The BRCT domain has been shown
to mediate the transcription function of BRCA1 (6, 7) and is a
phosphopeptide binding domain (8–10) that may be involved
in signal cascades in response to binding to phosphorylated
proteins. Apart from these two conserved domains, the central
region of BRCA1 encompassing f1,500 residues does not have
any identifiable domains.
Mutations in BRCA1 have been found inf40% of familial breast
cancer cases and in 80% of both familial breast and ovarian cancers
(11–13). Most cancer-predisposing mutations have been mapped
either to the RING or the BRCT domain, indicating the importance
of these two domains in the tumor suppressor function of
BRCA1. Cancer-predisposing mutations within the RING domain
of BRCA1 have been shown to correlate with the lack of ubiquitin
ligase function of BRCA1 (14). Cancer-associated mutations, and
not benign polymorphisms, in the BRCT domain of BRCA1 lead
to loss of its transcriptional activation function (15) and loss of
binding to RNA polymerase II (16). Mutations in the BRCT domains
of BRCA1 can also prevent it from being transported to the nucleus
for DNA damage repair (17).
BARD1 encodes a 777-residue protein and is structurally similar
to BRCA1, in that it has a RING domain (residues 46-90) at the
amino terminus and two tandem BRCT repeats (residues 616-653
and 743-777) at the carboxyl terminus. BARD1 interacts with
BRCA1 through the RING domains of the two proteins, although
there is evidence from our lab that these two proteins have
additional stabilizing interactions in domains distal to the RING
fingers (18). Unlike BRCA1, BARD1 mutations in breast cancer are
much less frequent (19, 20). Most of the functions of BARD1 are
associated with BRCA1. Independent functions of BARD1 involve
its roles in S-phase progression, contact inhibition nuclear division
(21), and apoptotic response to genotoxic stress (22).
In addition to its multiple nuclear functions, BRCA1 has been
shown to regulate centrosome function and duplication (23, 24).
Centrosomes are the microtubule nucleation centers of the cell.
Microtubules are an important component of cell cytoskeleton
affecting the basic functions of the cell: shape and polarity,
intracellular trafficking, motility, and cell division. Centrosome
abnormalities are common in many tumors including breast
cancer. Centrosomes in tumor cells exhibit hyperactivity; i.e., they
are larger and nucleate more microtubules than their normal
counterparts (25) and these centrosomes undergo numerical
amplification leading to abnormal mitoses and defective chromo-
somal segregation (26–28). In breast cells, the regulation of centro-
some number and function depends on BRCA1 (23, 24). We have
shown that BRCA1 can ubiquitinate centrosomal proteins and
this covalent modification renders the centrosome less active. We
identified g-tubulin as one of the centrosomal targets ubiquitinated
by BRCA1. g-Tubulin is a critical component of the g-tubulin ring
complex, which initiates microtubule nucleation.
In this study, we expanded prior results by showing that
expression of a stable but enzymatically inert mutant of the BRCA1
E3 ubiquitin ligase resulted in the same phenotype as BRCA1
knockdown in cells: centrosome amplification and hyperactivity.
We then mapped, using in vitro assays, the domains of BRCA1
and BARD1, which are necessary to inhibit the microtubule nuclea-
tion function of purified centrosomes. We reveal that both full-
length BRCA1 and BARD1 are required to regulate centrosome
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microtubule nucleation activity although the truncated versions
of BRCA1 and BARD1 were active ubiquitin ligases on another
substrate. The requirement for extra domains of BRCA1 and
BARD1, besides their respective RING domains, indicates that the
ubiquitination of centrosomes by the E3 ubiquitin ligase activity of
BRCA1/BARD1 is specific and dependent on multiple interaction
domains. Because our data showed that BARD1 was required along
with BRCA1 to regulate the centrosomes, we tested whether
BARD1 localized to centrosomes. We found that endogenous
BARD1 protein is present at the centrosomes throughout the cell
cycle. These findings reveal the functional domains of BRCA1 and
BARD1 in centrosome regulation.
Materials and Methods
Plasmids. BRCA1 (I26A) was made from the wild-type (wt) plasmid in
pcDNA3 (16) by using the Stratagene Quick Change Kit (Stratagene, La Jolla,
CA), incorporating the substituted amino acid using the primer sequence 5V-
CTTAGAGTGTCCCGCCTGTCTGGAGTTGATCAAGG-3Vprimer. Green fluo-
rescent protein (GFP)-centrin was a kind gift from Dr. Michel Bornens
(Institut Curie/UMR 144 du Centre National de la Recherche Scientifique,
Paris, France). BRCA1-Flag ( full-length and all deletion constructs) and
BARD1 baculoviruses were constructed according to FastBac system
(Invitrogen, Carlsbad, CA) as previously described (23).
Antibodies. Anti-g-tubulin and anti-a-tubulin (Sigma, St. Louis, MO)
were used at 1:1,000 dilution for both immunoblots as well as immu-
nofluorescence. Anti-BRCA1 (Ab-1; Oncogene, San Diego, CA) was used for
immunoblots at 1:100 dilution. BRCA1 and ubiquitin antibodies were raised
in rabbit and used at 1:1,000 for immunoblots. Anti-BARD1 antibody was
kindly provided by Dr. J. Harb (Institut National de la Sante et de la
Recherche Medicale, Nantes, France).
Cell culture and transfection. Hs578T (ATCC cell line HTB-126) and
HeLa S3 cells were cultured according to American Type Culture Collection
recommendations. Transfections with various plasmid DNAs were carried
out using Lipofectamine 2000 (Invitrogen) and protein expression and
phenotypic changes were observed 2 days posttransfection unless mentioned
otherwise. The GFP-centrin–encoding plasmid was cotransfected to mark
transfected cell centrosomes. Small interfering RNA (siRNA) transfection
was done using oligofectamine (Invitrogen). siRNA oligo targeting BRCA1
was designed from the 3Vuntranslated region (UTR) as described earlier (24).
The control GL2 oligonucleotide targets luciferase mRNA.
Microtubule regrowth assay. Cells were treated for 40 minutes with
chilled medium containing 25 Amol/L nocodazole to depolymerize micro-
tubules and then asters in cells were allowed to regrow in warm medium
without nocodazole for 2 to 15 minutes, as described earlier (24).
Immunofluorescence. Cells were treated with 200 Ag/mL saponin at
room temperature for 2 minutes and fixed in cold methanol before staining
with primary antibodies diluted 1:1,000 in 1 PBS containing 3% bovine
serum albumin and 0.1% Triton X-100.
For BARD1 staining, cells were fixed in methanol and the primary
antibody was used at 1:100 dilution. Cells were washed with PBS + 0.1%
Triton X-100 and stained with secondary antibodies. Images were viewed
using the 100 objective lens with a Nikon Eclipse TE2000-S microscope
and captured using a model 2.3.1 SPOT digital camera. Images were
processed using advanced SPOT software.
Protein purification. The BRCA1 and BARD1 baculoviruses were
coinfected in SF9 or Hi-Five insect cells using standard protocols and
purified using M2-agarose (Sigma) as described earlier (23). Protein
concentrations were determined after SDS-PAGE analysis by comparing
the intensities of Coomassie-stained polypeptides of BRCA1 and BARD1
with known protein standards.
Centrosome fractions were prepared from HeLa S3 cells according to
previously described protocol (29). Xenopus extract was prepared as
described earlier (30, 31).
In vitro ubiquitination and microtubule nucleation assays. Reactions
contained 0.5 BRB80 (80 mmol/L K-PIPES, 1 mmol/L MgCl2, 1 mmol/L
EGTA), 2 mmol/L ATP, 4 mmol/L MgCl2, 1 mmol/L ubiquitin, 200 nmol/L
E1, 5 Amol/L UbcH5c-his, and 5 to 60 nmol/L BRCA1/BARD1. Centrosome
fraction (f500-1,000 ng) was added to the reaction and incubated at 37jC
for 30 minutes. The reactions were transferred to ice and 10 AL of Xenopus
extract (20 mg/mL) were added and incubated at 23jC for 20 minutes to
allow aster formation. The asters were fixed with 1% glutaraldehyde and
spun through a 40% glycerol cushion onto glass coverslips precoated with
poly-L-lysine (http://mitchison.med.harvard.edu/protocols/spindown.html).
The asters were then fixed with cold methanol and visualized by immuno-
staining with anti-a-tubulin and anti-g-tubulin antibodies as described
in Materials and Methods (Immunofluorescence).
For densitometric quantification of the microtubule content of asters,
asters were photographed at 1,000 magnification, all using the same
exposure variables. Using the histogram tool in Adobe Photoshop, the
microtubule content of the asters was measured as the product of the mean
intensity and the number of pixels. The average values (F SE) were plotted
for 20 asters from each condition.
Results
An active BRCA1 E3 ubiquitin ligase is required to regulate
centrosomes in cells. Reducing BRCA1 protein levels by trans-
fecting cells with BRCA1-specific siRNA caused centrosome
hyperactivity (24). To study if the hyperactivity of centrosomes
could be corrected by providing exogenous BRCA1, Hs578T breast
cancer cells were transfected with a plasmid encoding wt BRCA1
or vector alone. A GFP-centrin plasmid was cotransfected to mark
the centrosomes of transfected cells. Twenty-four hours later, these
cells were transfected with either the control siRNA or the siRNA
designed to target the 3VUTR of BRCA1 (BRCA1c; ref. 24). The
transfected cells were subjected to microtubule regrowth assay
(described in ref. 24) in which microtubules were transiently
depolymerized by treating cells with nocodazole. Following
replacement of medium to remove the nocodazole, microtubules
regrew for 2 minutes, followed by fixing and staining for a-tubulin
(to mark microtubules). Cells were examined by fluorescence
microscopy and scored for the percentage cells with large asters
or those containing supernumerary (more than two) centrosomes.
Representative examples of cells containing small (Fig. 1Aa) or large
asters (Fig. 1Ab), two centrosomes (Fig. 1Ac), or more than two
centrosomes (Fig. 1Ad) are shown. Knockdown of BRCA1 expression
resulted in a 3-fold increase in the fraction of cells with large asters
(Fig. 1B , top) and a 2-fold increase in the fraction of cells with more
than two centrosomes (Fig. 1B, bottom) as compared with control
siRNA–transfected cells. On expression of exogenous BRCA1, which
is resistant to the 3VUTR-specific siRNA, the centrosome microtu-
bule nucleation activity and centrosome number in cells transfected
with BRCA1 siRNA were comparable to those in the control cells
(Fig. 1B). To test the levels of BRCA1 protein, lysates of cells
transfected with siRNAs and plasmids, as described above, were
probed with BRCA1-specific antibody. BRCA1 levels in the control
siRNA– and vector-transfected cells (Fig. 1C, lane 2) were identical
to those in cells transfected with neither (Fig. 1C, lane 1). BRCA1
siRNA transfection significantly decreased the levels of the protein
(Fig. 1C, lane 3). Expression of exogenous BRCA1 increased the levels
of the protein (Fig. 1C, lanes 4 and 5). These results indicated that
the effects of siRNA transfection on centrosome number and
function in Hs578T cells were indeed due to BRCA1 protein levels
and not due to an unknown off-target protein.
We tested whether expression of a stable, yet enzymatically inert,
BRCA1 E3 ubiquitin ligase would affect centrosome phenotype.
Hs578T cells were transfected with increasing amounts of BRCA1-
encoding plasmid or a plasmid encoding a mutant of BRCA1 (I26A)
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that lacked the ubiquitin ligase activity (32). A GFP-centrin
expression plasmid was used to mark transfected cell centrosomes.
Interestingly, expression of BRCA1 (I26A) profoundly affected the
number of cells with large asters. Vector-transfected (4 Ag pcDNA3
vector, 0 Ag pcDNA3-BRCA1 plasmid) and wt BRCA1–transfected
cells all hadf20% to 25% of the cells with large asters. By contrast,
transfection with BRCA1 (I26A) caused about half of the cells to
have hyperactive asters (Fig. 2A). When we scored in the same
experiment for cells with more than two centrosomes, BRCA1
(I26A) transfection caused a 6-fold increase in centrosome
amplification as compared with cells transfected with wt BRCA1
(Fig. 2B). The amounts of BRCA1 wt or I26A protein in lysates for
the same amount of plasmid used for transfections were
comparable, as seen by Western blot analysis (Fig. 2C). These
results clearly indicate that the BRCA1 E3 ubiquitin ligase activity
is important for maintaining centrosome number and function in
Hs578T cells growing in tissue culture.
The role of the BRCA1 carboxyl terminus in centrosome
regulation. We investigated whether other domains of BRCA1,
besides the RING domain, are important for the centrosome
regulation function of BRCA1. To avoid complications resulting
Figure 1. BRCA1 protein is required for in vivo regulation of centrosome
function and number. A, Hs578T cells were transfected with either the control
siRNA or BRCA1 3VUTR-specific siRNA with or without a cotransfected plasmid
expressing BRCA1. A GFP-centrin–expressing plasmid was included to mark
transfected cell centrosomes. Forty-eight hours posttransfection, cells were
subjected to the microtubule regrowth assay. Microtubules were detected by
staining for a-tubulin. A, a to d, bar, 10 Am. B, the percentage of cells with either
small asters (Aa) or large asters (Ab ) was scored for 100 to 150 cells. Histogram
of the percentage of cells with large asters (top ) and, taken from the same slide,
histogram of the percentage of cells with more than two centrosomes (bottom ).
Columns, mean of two independent experiments; bars, SE. C, immunoblots of
total cell lysates from cells transfected with the control siRNA (lanes 2 and 4 ),
BRCA1 siRNA (lanes 3 and 5), 4 Ag of either vector (lanes 2 and 3) of plasmid
encoding BRCA1 (lanes 4 and 5), and no siRNA and plasmid DNA (lane 1)
were probed for BRCA1. a-Tubulin levels served as loading control.
Figure 2. BRCA1-dependent ubiquitin ligase activity is required for in vivo
regulation of centrosome function and duplication. A, Hs578T cells were
transfected with 2, 3, or 4 Ag of plasmid expressing either BRCA1 (wt) or
enzymatically inert BRCA1 (I26A). GFP-centrin was used as a transfection and
centrosome marker as in Fig. 1. Forty-eight hours posttransfection, cells were
subjected to the microtubule regrowth assay and microtubules were detected by
staining for a-tubulin as above. The percentage of cells containing large asters
was scored for 100 to 150 cells. Points, mean of two independent experiments;
bars, SE. B, using the same cells as in (A ), the percentage of cells with more
than two centrosomes was scored. C, immunoblots of total cell lysates from cells
transfected with the indicated quantity of plasmid expressing either BRCA1
(wt) (lanes 4-6) or BRCA1 (I26A) (lanes 1 -3) were probed for BRCA1 and also
for a-tubulin levels as loading control.
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from unequal expression of deletion mutants in vivo , we tested
these mutant proteins in vitro in reactions where the concentra-
tion of a given protein is rigorously controlled. We purified various
deletions of Flag-tagged BRCA1 in heterodimeric complex with
BARD1 from insect cells. Full-length Flag-tagged BRCA1(1-1,863),
BRCA1(1-1,852), BRCA1(1-1,527), BRCA1(1-1,000), BRCA1(D303-
770), and BRCA1(D770-1,290) were each coexpressed with
untagged BARD1 and purified via the epitope tag. These protein
preparations were balanced for their BRCA1 content (Figs. 3A
and 4A) and used in the in vitro aster formation assay (described
in ref. 24). Centrosomes purified from HeLa S3 cells were
incubated in the presence of varying quantities of the different
BRCA1 deletions in complex with BARD1, along with ubiquitin
activating enzyme (E1), conjugating enzyme (UbcH5c/E2), and
ubiquitin. The ubiquitinated centrosomes were then assayed for
aster formation function by incubation with Xenopus extract.
The asters were fixed and stained for microtubule (using an
anti-a-tubulin antibody) and centrosomes (using anti-g-tubulin
antibody) and the microtubule content of 20 randomly selected
asters was quantitated in each reaction. Representative asters
from the control reaction (without any BRCA1) and reactions
containing 30 nmol/L of the various BRCA1/BARD1 preparations
are shown in Fig. 3Ba .
All carboxyl-terminal deletion preparations of BRCA1 in
association with BARD1 had approximately equal in vitro ubiquitin
ligase activities when using the phosphorylated RNA polymerase II
as a substrate (23) or in polymerizing ubiquitin chains (data not
shown), but the following results indicate that deletions in BRCA1
affect the regulation of the centrosome. BRCA1(1-1,852)/BARD1
lacks 11 amino acids from the carboxyl terminus and was as
effective as the full-length protein in inhibiting centrosome
function (Fig. 3Bb). BRCA1(1-1,527)/BARD1, lacking the carboxyl-
terminal 336 amino acids, was 4-fold less effective compared with
the full-length protein at 30 nmol/L, although at 60 nmol/L
BRCA1(1-1,527)/BARD1, the inhibition of aster formation was
reduced to 40% of the control reaction (Fig. 3Bb). At 60 nmol/L
concentration of BRCA1(1-1,000)/BARD1, the centrosome aster
microtubule content was reduced to 60% of the control reaction
(data not shown). This level of inhibition was similar to that
observed with BRCA1(1-500)/BARD1 at the same concentration
of enzyme (24), and we judge this low level of inhibition to be
nonspecific. Taken together, these results clearly indicate that the
Figure 3. Domains of BRCA1 critical for
inhibiting centrosome function in vitro . A,
BRCA1 protein lacking different regions of the
protein as indicated were coexpressed with
BARD1 in insect cells and purified via the
5V-Flag tag present on BRCA1. Silver-stained
gels containing either 0.5 (+) or 1 (++) pmol of
the various protein preparations as indicated.
The BRCA1 band was marked with an
asterisk. B, all of the protein preparations were
normalized for BRCA1 content and used in an
in vitro microtubule nucleation assay using
centrosomes purified from HeLa S3 cells.
Purified centrosomes were ubiquitinated with
E1, E2 (UbcH5c), and varying concentrations
of BRCA1/BARD1 (B/B ) protein preparations.
7.5, 15, and 30 nmol/L proteins were used for
B(1-1,863)/B, B(1-1,852)/B, and B(1-1,527)/B,
and 10, 15, 20, and 30 nmol/L proteins were
used for B(D303-770)/B. The ubiquitinated
centrosomes were allowed to grow
microtubule by addition of Xenopus extract,
and the resulting asters were centrifuged onto
coverslips and stained for g-tubulin and
a-tubulin to mark centrosomes and
microtubule, respectively. Although two colors
were used in immunofluorescence microscopy,
these black and white images faithfully show
the centrosomes as bright centers in the
microtubule asters. a, representative fields
containing asters from reactions containing
30 nmol/L of the different BRCA1 deletions;
bar, 10 Am. Twenty asters were photographed
under same exposure and the microtubule
content determined. The mean values
obtained for each condition were normalized
with the control reaction containing
centrosomes and ubiquitination factors but no
BRCA1. b, points, normalized mean for each
condition (expressed as microtubule content);
bars, SE.
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carboxyl-terminal 336 amino acids of BRCA1 are important for
the inhibition of centrosome function.
Internal domains of BRCA1 and the regulation of centro-
some function. BRCA1 has been shown to bind g-tubulin via
amino acid residues 504-803 and the amino-terminal portion of
this peptide fragment (residues 510-622) was required for binding
to g-tubulin (33). We tested whether this reported g-tubulin
binding domain affected centrosome function. We made two
internal deletions of BRCA1, BRCA1(D303-770) that removes
the required portion of the g-tubulin binding domain and
BRCA1(D770-1,290) that deletes the region downstream to the
g-tubulin binding domain. We expressed these internal deletion
mutants along with BARD1, as above, and purified the mutant
BRCA1/BARD1 heterodimers.
BRCA1(D303-770)/BARD1 had only a marginal effect at concen-
trations lower than 20 nmol/L, but at 30 nmol/L BRCA1(D303-770)/
BARD1, inhibition of aster formation was as effective as observed
with the full-length protein (Fig. 3Bb). This result indicates that
the reported g-tubulin binding domain is stimulatory, but not
essential, for BRCA1/BARD1 regulation of centrosomes.
At low concentration (7.5 nmol/L), BRCA1(D770-1,290)/BARD1
caused an 85% reduction in microtubule content compared with
control (Fig. 4B). At higher concentrations, this BRCA1(D770-
1,290)/BARD1 apparently aggregated (as observed from two
independent preparations; data not shown), but this deletion was
clearly as active as the wt protein. The effect of this internal
deletion mutant was dependent on the presence of ubiquitin in the
reaction (data not shown), emphasizing the role of the E3 ligase
activity in causing the inhibition to centrosome activity. To
reconfirm that the inhibition was specific, we included in reactions
a peptide fragment of RNA helicase A, which we call the BRCA1
inhibitory fragment. BRCA1 inhibitory fragment is a fragment of
the RNA helicase A protein (residues 89-344) that interacts with
BRCA1 and functionally inhibits it (34). This polypeptide was
shown earlier to inhibit the BRCA1/BARD1–mediated ubiquitina-
tion of g-tubulin (23) and to reverse the inhibition of centrosome
aster formation in vitro by BRCA1/BARD1 (24). The control peptide
contains an overlapping fragment of RNA helicase A (residues
1-250) that lacks the BRCA1 binding domain. Inclusion in reac-
tions of BRCA1 inhibitory fragment polypeptide blocked the inhi-
bition of centrosome function by BRCA1(D770-1,290)/BARD1.
Inclusion in reactions of the control polypeptide only had a minor
effect on aster formation. Thus, the decrease in microtubule
content of asters by BRCA1(D770-1,290)/BARD1, along with other
ubiquitination factors, was specific and was partially reversed by
adding BRCA1 inhibitory fragment polypeptide to the reaction.
From these results, we concluded that sequences of BRCA1 from
residues 770-1,290 were dispensable with regard to centrosome
regulation, but these residues contributed to the overall solution
stability of BRCA1. Results for the various BRCA1 deletion proteins
are summarized in Fig. 5. Only full-length (residues 1-1,863), an
11-amino-acid truncation (residues 1-1,852), and the 520-amino-
acid internal deletion (D770-1,290) had maximum inhibition of
centrosome function. With the exception of the enzymatically inert
I26A mutation, all of these proteins had approximately equal
nonspecific ubiquitin ligase activity (ref. 35 and data not shown).
We compared all of these protein preparations for the specific
monoubiquitination of g-tubulin. In an earlier study (23), we had
shown that at 15 nmol/L BRCA1/BARD1, only full-length BRCA1/
BARD1 had high g-tubulin ubiquitination activity, and the
BRCA1(1-1,852)/BARD1 protein had lower levels of this specific
activity. At higher concentrations of protein, very low levels of
ubiquitination of g-tubulin were detectable by all of these deletion
mutants (ref. 24 and data not shown). The two internal deletions of
BRCA1 also weakly modified g-tubulin (at 30 nmol/L; Fig. 4C , lanes
2 and 3). The results of centrosome function inhibition roughly
correlate with the extent of monoubiquitination of g-tubulin for
each protein. These results are consistent with a key role of
g-tubulin modification in this reaction, but certainly, other un-
known substrates within the centrosome may also be important.
The carboxyl-terminal 485 amino acids of BARD1 are
required for inhibition of centrosome function by BRCA1.
Because all the BRCA1 protein preparations tested in the in vitro
Figure 4. An internal domain of BRCA1 is dispensable for centrosome
regulatory function. A, BRCA1(D770-1,290)/BARD1 was coexpressed with
BARD1 in insect cells and copurified. 0.5 pmol (lane 4) and 1 pmol (lane 3 ) of
this protein were loaded along with 0.5 pmol (lane 2) and 1 pmol (lane 1)
BRCA1(1-1,863)/BARD1 and detected by silver staining. B, 7.5 nmol/L
BRCA1(D770-1,290)/BARD1 was tested in the in vitro microtubule nucleation
assay with purified centrosomes, E1, E2, and ubiquitin. The BRCA1 inhibitory
fragment or the control peptide, at 3.5 Amol/L, was added to the reaction as
indicated. The normalized microtubule content for 20 asters was calculated and
plotted for each reaction condition. C, centrosomes purified from HeLa cells were
incubated with ubiquitination factors and different BRCA1/BARD1 proteins at
30 nmol/L concentration, and proteins were analyzed by immunoblot analysis
using a monoclonal antibody specific for human g-tubulin. Arrow, ubiquitinated
g-tubulin.
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aster formation assay contained BARD1, we tested if BARD1 was
essential. BRCA1 alone can ubiquitinate target proteins, although
far less strongly than when associated with BARD1 (2, 3, 14).
BARD1 by itself does not exhibit E3 ubiquitin ligase activity
in vitro (4). When 30 nmol/L BRCA1 alone was used in the in vitro
assay, it failed to inhibit centrosome aster formation (Fig. 6B). Flag-
tagged BRCA1 was coexpressed with a truncated BARD1 protein
[BARD1(1-292)] that had the RING domain but lacked the 485
amino acid residues from the carboxyl terminus. BRCA1(1-1,863)/
BARD1(1-292) was balanced for BRCA1 content (Fig. 6A) and
tested in the in vitro aster formation assay. BRCA1(1-1,863)/
BARD1(1-292) is a functional ubiquitin ligase and ubiquitinates
Npm1, a known target for BRCA1 (data not shown); synthesizes
ubiquitin polymers in the absence of target proteins (data not
shown); and weakly ubiquitinates g-tubulin (Fig. 6C). BRCA1-
(1-1,863)/BARD1(1-292) at 30 nmol/L only partially inhibited
centrosome microtubule nucleation (60%) relative to the control
reaction (Fig. 5B). These results reveal that full-length BARD1,
along with BRCA1, has the highest activity in inhibiting the
microtubule nucleation of centrosomes.
BARD1 is localized to centrosomes at all phases of the cell
cycle. BARD1 has been shown to localize predominantly to the
nucleus throughout the cell cycle (36). We had found that
although BRCA1 has highest concentrations during S phase, and
that most of the S and G2 phase BRCA1 is nuclear, there is a
relatively constant amount of BRCA1 associated with the
centrosome throughout the cell cycle (24). Because BARD1 is
required for the BRCA1-dependent regulation of centrosome
function, we examined whether BARD1 was localized at centro-
somes in vivo . For this purpose, Hs578T cells were treated with
nocodazole to depolymerize microtubules. This ensured that
only proteins strongly associated with centrosomes were detected.
Extraction with saponin reduced the background stain due to the
presence of cytosolic proteins. The cells were fixed with methanol
and stained with g-tubulin, to mark centrosomes, and with
BARD1 antibodies. From the asynchronous cell population, cells
from different cell cycle phases were identified based on the
position of centrosomes. It was observed that BARD1 colocalized
with centrosomes during the G1-S, S, and M phases of the cell
cycle (Supplementary Fig. S1). During S phase, BARD1 was
predominantly nuclear and formed speckles similar to BRCA1. At
G1-S, BARD1 was not detected in the nucleus and was predo-
minantly centrosomal. From these immunofluorescence data, it
was clear that BARD1 was present along with BRCA1 at the
centrosome to regulate its function.
Discussion
For several years, it has been known that BRCA1 localizes to
centrosomes during mitosis and disruption of BRCA1 in murine
cells caused centrosome amplification (33, 37, 38), but a mecha-
nistic explanation for how BRCA1 regulates centrosomes was
unknown. In prior work, we found that transient inhibition of
BRCA1 caused centrosome amplification in human breast cell
lines but not in cell lines derived from other tissues (23). We
found that BRCA1-dependent ubiquitination activity could modify
several centrosome proteins, including g-tubulin, and that the
g-tubulin modification was important for centrosome regulation
(23). We recently applied the established in vitro functional assay
of microtubule nucleation to reveal regulation by the BRCA1/
BARD1 E3 ubiquitin ligase (24). In the present study, using an
in vitro functional assay dependent on the BRCA1/BARD1
ubiquitin ligase activity, we mapped domains of each protein
that are necessary to regulate centrosome function. Although
Figure 5. BRCA1 domains required for
efficient inhibition of centrosome function
and for ubiquitination of g-tubulin. Data are
summarized in this schematic of different
BRCA1 constructs used in the study in
association with BARD1. Effects of the
different proteins on inhibition of
centrosome microtubule nucleation and on
g-tubulin monoubiquitination. With regard
to centrosome inhibition: +++, 70%
inhibition at BRCA1/BARD1 concentrations
of 15 nmol/L or less; ++, >70% inhibition at
30 nmol/L; +, >50% inhibition at 60 nmol/L;
+/, <50% inhibition at 60 nmol/L. With
regard to g-tubulin ubiquitination tested at
30 nmol/L BRCA1/BARD1: +++, most
efficient ubiquitination as seen for
full-length BRCA1 and BARD1; ++, f50%
of the efficiency of the full-length protein;
+, <50%.
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carboxyl-terminal truncations of each BRCA1 and BARD1 could
produce active E3 ubiquitin ligases, only heterodimers of the full-
length BRCA1 and BARD1 regulate centrosome function. An
internal deletion of BRCA1, removing amino acids 770-1,290, was
equivalent in centrosome regulating activity when compared with
the full-length protein, but all other deletions of BRCA1 or BARD1
tested were diminished in activity. Thus, a large amount of the
BRCA1 protein sequence is necessary for the regulation of
centrosomes.
The expression in cells of the BRCA1 (I26A) mutant, which
lacks E3 ubiquitin ligase activity, had a dominant-negative
phenotype of centrosome amplification and centrosome hyperac-
tivity (Fig. 2). This result is the first proof that the in vitro
functions we previously revealed (24) apply also to BRCA1
function in the cell. We had also observed that the expression
of an amino-terminal deletion mutant of BRCA1 (containing
residues 301-1,863) disrupted centrosome regulation in a breast
cell line (39), but in that case BRCA1 would not stably interact
with BARD1. In the experiment in Fig. 2B , the BRCA1 (I26A) is
stable and dimerizes fully with BARD1, but it cannot bind to the
E2 factor (32) and is thus inactive as E3 ligase. That expression
of this mutant dominantly causes centrosome disruption indicates
that BRCA1 function at this organelle requires its ubiquitin ligase
activity.
Nearly the full-length of BRCA1 is required for full regulation
of centrosome microtubule nucleation function. The requirement
for the carboxyl terminus likely is dependent on specificity for
binding to substrates on the centrosome. Because BARD1 is
required for centrosome regulation, another possibility is that
the carboxyl terminus of BRCA1 is required to stabilize BARD1 in
the heterodimer. We have recently found that the BRCA1 carboxyl
terminus stabilizes BARD1 heterodimerization. Without the
BRCA1 carboxyl terminus, the quantity of BARD1 binding to
BRCA1 drops significantly (18). However, when we renormalized
the data in Fig. 3 according to the BARD1 concentrations of
each BRCA1 mutant/BARD1 heterodimer, we found that the
effects on centrosome microtubule nucleation did not signifi-
cantly correlate with the amount of BARD1 present in the
reaction (data not shown). Thus, we infer that the requirement
for the carboxyl terminus of BRCA1 in the ubiquitination-
dependent regulation of centrosome function is, in fact, due to
substrate binding.
We have observed that multiple centrosome proteins are
ubiquitination substrates of BRCA1/BARD1 in vitro , and one of
these is g-tubulin (23). The ubiquitination of g-tubulin is clearly
important because expression of mutant g-tubulin molecules that
can no longer be ubiquitinated by BRCA1/BARD1 results in the
dominant phenotype of centrosome amplification and centro-
some hyperactivity (23, 24). The amount of g-tubulin ubiquitina-
tion in these reactions is low, and it is unclear whether the
activity of the centrosomes in the in vitro reaction is, in fact,
regulated entirely by g-tubulin ubiquitination. On the other hand,
the analysis of the deletion mutants of BRCA1 and BARD1 in this
study reveals that the level of g-tubulin ubiquitination in vitro
roughly correlates with effectiveness in inhibiting microtubule
nucleation. The ubiquitination of g-tubulin may serve as a
surrogate marker for efficiency of ubiquitinating centrosome
proteins in general. However, the BRCA1(D303-770)/BARD1
construct ubiquitinates g-tubulin weakly, and yet that deletion
mutant of BRCA1 strongly inhibits centrosome function in vitro .
Summarizing these observations, it is evident that there are
other ubiquitination candidates at the centrosome modified by
BRCA1/BARD1. Whereas the regulation of centrosome function
by the BRCA1/BARD1 E3 ubiquitin ligase is complex, loss of
this activity in breast cells mimics the pathogenesis of breast
cancer.
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Figure 6. Full-length BARD1 is required for BRCA1-mediated inhibition of
centrosome microtubule nucleation in vitro . A, BARD1 lacking its
carboxyl-terminal 485 amino acids, BARD1(1-292), was coexpressed with
5V-Flag-tagged BRCA1 in insect cells and purified. Silver-stained gel containing
1 pmol BRCA1(1-1,863)/BARD1(1-770) (lane 1) and BRCA1(1-1,863)/
BARD1(1-292) at 0.5 pmol (lane 2) and 1 pmol (lane 3). B, the effect of BARD1
on the in vitro microtubule nucleation assay was tested using 30 nmol/L BRCA1
alone, 30 nmol/L BRCA1/BARD1(1-770), or 30 nmol/L BRCA1/BARD1(1-292).
As in other experiments, the microtubule content of 20 asters was determined
and normalized with respect to the control sample that did not contain BRCA1/
BARD1. Columns, normalized mean; bars, SE. C, centrosomes were incubated
with ubiquitination factors and different BRCA1/BARD1 proteins at 30 nmol/L
and were analyzed by immunoblot analysis using an antibody specific for human
g-tubulin.
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